Get the Stockscreener App
30.70
1.92%
-0.60
After Hours:
30.70
Bridgebio Pharma Inc stock is traded at $30.70, with a volume of 2.12M.
It is down -1.92% in the last 24 hours and up +23.44% over the past month.
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.
See More
Previous Close:
$31.30
Open:
$31.38
24h Volume:
2.12M
Relative Volume:
1.05
Market Cap:
$5.77B
Revenue:
$218.60M
Net Income/Loss:
$-538.26M
P/E Ratio:
-7.8718
EPS:
-3.9
Net Cash Flow:
$-605.72M
1W Performance:
+10.23%
1M Performance:
+23.44%
6M Performance:
+4.24%
1Y Performance:
+4.10%
1-Day Range:
$29.72
$32.05
1-Week Range:
$27.80
$32.06
52-Week Range:
$21.62
$44.32
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Name
Bridgebio Pharma Inc
Sector
Industry
Phone
(650) 391-9740
Address
3160 PORTER DR., PALO ALTO, CA
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-31-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-07-23 | Initiated | Citigroup | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-18-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-19-23 | Initiated | Evercore ISI | Outperform |
| Feb-06-23 | Initiated | Cowen | Outperform |
| Dec-27-21 | Reiterated | Mizuho | Buy |
| Dec-27-21 | Reiterated | SVB Leerink | Outperform |
| Sep-10-21 | Upgrade | BofA Securities | Neutral → Buy |
| May-21-21 | Initiated | UBS | Buy |
| Mar-22-21 | Reiterated | Goldman | Buy |
| Feb-22-21 | Resumed | JP Morgan | Overweight |
| Feb-09-21 | Resumed | Goldman | Buy |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Neutral |
| May-19-20 | Initiated | BTIG Research | Buy |
| Apr-13-20 | Initiated | H.C. Wainwright | Buy |
| Feb-19-20 | Initiated | Mizuho | Buy |
| Jul-26-19 | Initiated | Raymond James | Outperform |
| Jul-22-19 | Initiated | BMO Capital Markets | Outperform |
| Jul-22-19 | Initiated | Goldman | Buy |
| Jul-22-19 | Initiated | JP Morgan | Overweight |
| Jul-22-19 | Initiated | Jefferies | Buy |
| Jul-22-19 | Initiated | Piper Jaffray | Overweight |
| Jul-22-19 | Initiated | SVB Leerink | Outperform |
View All
Bridgebio Pharma Inc Stock (BBIO) Latest News
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - StockTitan
BridgeBio Pharma (NASDAQ:BBIO) Trading Up 4.8% - MarketBeat
BridgeBio stock gains as Piper sets bullish view (NASDAQ:BBIO) - Seeking Alpha
Piper Sandler Initiates Coverage on BridgeBio Pharma (NASDAQ:BBIO) - MarketBeat
Piper Sandler Initiates Coverage of BridgeBio Pharma (BBIO) with Overweight Recommendation - MSN
BridgeBio Pharma (NASDAQ:BBIO) Sees Large Volume Increase - MarketBeat
HC Wainwright Reaffirms Buy Rating for BridgeBio Pharma (NASDAQ:BBIO) - MarketBeat
Stock Watch: Do Regeneron And BridgeBio Stock Movements Signal Smarter Investors? - Scrip
Principal Financial Group Inc. Has $28.50 Million Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Pharma’s Formation of GondolaBio - Global Legal Chronicle
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Short Interest Down 9.7% in August - MarketBeat
Why Is BridgeBio Pharma Stock Trading Higher On Friday? - MSN
BridgeBio: With HELIOS-B Overhang Removed, Focus To Turn To Approval And Launch Of Acoramidis - Seeking Alpha
Panagora Asset Management Inc. Buys 312,686 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BRIDGEBIO PHARMA INVESTIGATION INITIATED by Former Louisiana Att - WICZ
BRIDGEBIO PHARMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates BridgeBio Pharma, Inc.BBIO - Business Wire
Alnylam stock falls, BridgeBio stock gains on ATTR-CM data - Seeking Alpha
Why Is BridgeBio Pharma Stock Trading Higher On Friday? - Benzinga
BridgeBio Pharma (NASDAQ:BBIO) Shares Gap Up to $24.62 - MarketBeat
BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and - The Bakersfield Californian
BridgeBio Shares Data on Serum TTR Increase When Switching - GlobeNewswire
BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension - StockTitan
Alnylam Shares Dive After Heart Drug Fails To Meet Expectations - Finimize
Alnylam shares slide after heart drug data fails to impress investors - Reuters
Ainylam Pharmaceuticals shares tumble following study results, BridgeBio Pharma rises - Investing.com Australia
Ainylam Pharmaceuticals shares tumble following study results, BridgeBio Pharma rises By Investing.com - Investing.com South Africa
Ainylam Pharmaceuticals shares tumble following study results, BridgeBio Pharma rises - Investing.com
Ainylam Pharmaceuticals shares tumble following study results, BridgeBio Pharma rises - Investing.com UK
BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension - Yahoo Finance
BBIOBridgeBio Pharma, Inc. Latest Stock News & Market Updates - StockTitan
BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024 - GlobeNewswire
BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024 - StockTitan
BridgeBio Pharma to Participate in September Investor Events - GlobeNewswire
BridgeBio Pharma to Participate in September Investor Events - StockTitan
BridgeBio Partners with Leading Cardiovascular Data Science - GlobeNewswire
BridgeBio and Yale initiate AI study for heart disease detection - Investing.com
BridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificial Intelligence - StockTitan
A Bridgebio not far: PDUFA looms for acoramidis, firm keeps busy - BioWorld Online
BridgeBio: PDUFA Date Expected In November 2024 Could Shift Momentum (NASDAQ:BBIO) - Seeking Alpha
(BBIO) Trading Signals - Stock Traders Daily
BridgeBio launches another new company, GondolaBio - The Pharma Letter
BridgeBio Launches GondolaBio With $300M, Transfers Programs to Joint Venture - BioSpace
BridgeBio Pharma's (BBIO) Buy Rating Reiterated at HC Wainwright - MarketBeat
BridgeBio Pharma’s (BBIO) Buy Rating Reiterated at HC Wainwright - Defense World
BridgeBio Pharma forms joint venture, GondolaBio, with $300M investment By Investing.com - Investing.com India
BridgeBio sends rare disease drugs to new company - BioPharma Dive
BridgeBio Pharma forms joint venture, GondolaBio, with $300M investment By Investing.com - Investing.com Australia
BridgeBio Pharma forms joint venture, GondolaBio, with $300M investment By Investing.com - Investing.com
BridgeBio Pharma forms joint venture, GondolaBio, with $300M investment By Investing.com - Investing.com UK
BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Brian C. Stephenson Sells 4,155 Shares - Defense World
Bridgebio Pharma Inc Stock (BBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bridgebio Pharma Inc Stock (BBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| STEPHENSON BRIAN C | Secretary, Treasurer & CFO |
Aug 19 '24 |
Sale |
24.69 |
4,155 |
102,590 |
85,192 |
1.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):